Influenza virus infection
Conditions
Interventions
None listed
Sponsors
Shionogi & Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1, Patients whose the date of earliest diagnosis of influenza virus infection is within each influenza season (day 1) during the enrollment period of each influenza season (October 1, 2018 to April 17, 2019, or October 1, 2019 to April 17, 2020) and patients has an observable period from 6 months before Day 1 (that is, the observation start date in the parameter table is more than 6 months before the month of Day 1). Influenza virus infection is defined by the ICD-10 small classification code without a suspicion flag. 2, Patients with BXM, OTV, ZNV, or LNV administration date as anti-influenza virus drugs on Day 1.
Exclusion criteria
Exclusion criteria: 1, Patients with an admission receipt or DPC receipt with the date of admission from 90 days before Day 1 2, Patients who have administration dates of an antibacterial drugs from 90 days prior to Day 1 3, Patients who has a diagnosis (no suspicion flag) of pneumonia in receipts for the past 3 months from the month with Day 1 to excluding the month with Day 1, or has a medical starting date before Day 1 to including Day 1 in receipts for the month including Day 1. 4, Patients who have infusions on Day 1 5, Patients with febrile seizures on Day 1 with medical starting date (no suspicion flag) 6, Patients who died on Day 1 (Patients for whom "terminate in death" is described in the disease name in the receipt for the month including Day 1 and whose last date of medical treatment in the receipt is the same as Day 1). 7, Patients under 5 years old or 12 years old or older as of Day 1 8, Patients with multiple influenza anti-influenza drugs (BXM, OTV, ZNV, LNV, or PRV) dispensing dates on Day 1.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization incidence (days 2-14) with the date of diagnosis of influenza infection as Day 1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of each of the following events from Day 2 to Day 14 - Antibacterial oral administration - Antibacterial injectable administration - Pneumonia - Additional anti-influenza drug use - Infusion - Febrile seizures - Each secondary end points with hospitalization | — |
Countries
Japan
Contacts
Public ContactShogo Miyazawa
Shionogi & Co., Ltd. Data Science Department
Outcome results
None listed